Global Lifestyle Drugs Market 2017-2021 - Product Image

Global Lifestyle Drugs Market 2017-2021

  • ID: 4115425
  • Report
  • Region: Global
  • 91 pages
  • TechNavio
OFF
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 5

FEATURED COMPANIES

  • Acerus Pharmaceuticals
  • BMS
  • Euthymics Bioscience
  • Ion Channel Innovations
  • Novan
  • S1 Biopharma
  • MORE
About Lifestyle Drugs Market

Lifestyle disease is associated with the way an individual or group of people live. Some of the lifestyle diseases include depression, sexual dysfunction, anti-aging, baldness, and obesity.

The analysts forecast the global lifestyle drugs market to grow at a CAGR of 2.87% during the period 2017-2021.

Covered in this report
The report covers the present scenario and the growth prospects of the global lifestyle drugs market for 2017-2021. To calculate the market size, the report considers sales of lifestyle drugs in the market.

The market is divided into the following segments based on geography:
- Americas
- EMEA
- APAC

The report, Global Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the Key vendors operating in this market.

Key vendors
- Allergan
- BMS
- Eli Lilly
- Pfizer

Other prominent vendors
- Acerus Pharmaceuticals
- Alkermes
- Amorepacific
- AndroScience
- Anterios
- AstraZeneca
- Avanir Pharmaceuticals
- Avolynt
- Celtaxsys
- Cerecor
- Corcept Therapeutics
- Cosmo Pharmaceuticals
- CTC Bio
- Dermira
- Dong-A ST
- Euthymics Bioscience
- Foamix
- Follicum
- Forendo Pharma
- Futura Medical Developments
- Galderma
- Hanmi Pharmaceutical
- Incyte
- Intrepid Therapeutics
- Ion Channel Innovations
- iX Biopharma
- Johnson & Johnson
- Legacy Healthcare
- LEO Pharma
- H. Lundbeck
- Luye America Pharmaceuticals
- Merck
- Minerva Neurosciences
- MSI Methylation Sciences
- Neuralstem
- Novan
- Novartis
- Novo-Nordisk
- Palatin Technologies
- Paratek Pharmaceuticals
- Photocure
- Revance Therapeutics
- Rhythm Pharmaceuticals
- S1 Biopharma
- Sage Therapeutics
- Samumed
- Sanofi
- Sigma-Tau Pharmaceuticals
- Strategic Science & Technologies
- Sumitomo Dainippon Pharma
- Takeda
- TetraLogic Pharmaceuticals
- TherapeuticsMD
- Valeant Pharmaceuticals
- VistaGen Therapeutics
- VIVUS
- XBiotech
- Yuhan
- Zafgen

Market drivers
- Lifestyle changes
- For a full, detailed list, view the full report

Market challenges
- Patent expiries
- For a full, detailed list, view the full report

Market trends
- Increase in M&A
- For a full, detailed list, view the full report

Key questions answered in this report
- What will the market size be in 2021 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

You can request one free hour of the analyst’s time when you purchase this market report. Details are provided within the report.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Acerus Pharmaceuticals
  • BMS
  • Euthymics Bioscience
  • Ion Channel Innovations
  • Novan
  • S1 Biopharma
  • MORE
PART 01: Executive summary

PART 02: Scope of the report

PART 03: Research Methodology

PART 04: Introduction

Key market highlights

PART 05: An overview of lifestyle diseases

PART 06: Market landscape

Market overview

Five forces analysis

PART 07: Pipeline landscape

PART 08: Market segmentation by therapy area

Depression

Dermatology (acne, anti-aging, and baldness)

Sexual dysfunction

Obesity

PART 09: Geographical segmentation

Lifestyle drugs market in Americas

Lifestyle drugs market in EMEA

Lifestyle drugs market in APAC

PART 10: Market drivers

Lifestyle changes

Development of novel therapeutics

Increasing demand from older population

PART 11: Impact of drivers

PART 12: Market challenges

Patent expiries

Side effects coupled with product recalls

Presence of alternative therapies and treatments

PART 13: Impact of drivers and challenges

PART 14: Market trends

Increase in M&A

Growing focus on development of drugs for new indications

Emerging lifestyle diseases

PART 15: Vendor landscape

Competitive scenario

PART 16: Key vendor analysis

Allergan

BMS

Eli Lilly

Pfizer

Other prominent vendors

PART 17: Appendix

List of abbreviation

PART 18: About the Author

List of Exhibits
Exhibit 01: Global lifestyle drugs market snapshot
Exhibit 02: Global lifestyle drugs market 2016-2021 ($ billions)
Exhibit 03: Opportunity analysis in global lifestyle drugs market
Exhibit 04: Five forces analysis
Exhibit 05: Pipeline analysis of vendors in Phase III
Exhibit 06: Key pipeline drugs for depression 2016
Exhibit 07: Key pipeline drugs for dermatology (anti-aging, baldness, and acne) 2016
Exhibit 08: Key pipeline drugs for sexual dysfunction 2016
Exhibit 09: Key pipeline drugs for obesity
Exhibit 10: Global depression drugs market 2016-2021 ($ billions)
Exhibit 11: Global dermatology lifestyle drugs market 2016-2021 ($ billions)
Exhibit 12: Global sexual dysfunction drugs market 2016-2021 ($ billions)
Exhibit 13: Global obesity drugs market 2016-2021 ($ billions)
Exhibit 14: Segmentation of global lifestyle drugs market by geography 2016 and 2021
Exhibit 15: Global lifestyle drugs market revenue by geography 2016-2021 ($ billions)
Exhibit 16: Market scenario in Americas
Exhibit 17: Lifestyle drugs market in Americas 2016-2021 ($ billions)
Exhibit 18: Market scenario in EMEA
Exhibit 19: Lifestyle drugs market in EMEA 2016-2021 ($ billions)
Exhibit 20: Market scenario in APAC
Exhibit 21: Lifestyle drugs market in APAC 2016-2021 ($ billions)
Exhibit 22: Impact of drivers
Exhibit 23: Impact of drivers and challenges
Exhibit 24: Competitive structure analysis of global lifestyle drugs market 2016
Exhibit 25: Competitive analysis of global lifestyle drugs market
Exhibit 26: Market penetration of various lifestyle drug manufacturers worldwide 2016
Exhibit 27: Strategic success factors of companies in global lifestyle drugs market
Exhibit 28: Allergan: Key highlights
Exhibit 29: Allergan: Strength assessment
Exhibit 30: Allergan: Strategy assessment
Exhibit 31: Allergan: Opportunity assessment
Exhibit 32: BMS: Strength assessment
Exhibit 33: BMS: Strategy assessment
Exhibit 34: BMS: Opportunity assessment
Exhibit 35: BMS: YoY and growth rate of Abilify 2013-2015 ($ billions)
Exhibit 36: Eli Lilly: Key highlights
Exhibit 37: Eli Lilly: Strength assessment
Exhibit 38: Eli Lilly: Strategy assessment
Exhibit 39: Eli Lilly: Opportunity assessment
Exhibit 40: Eli Lilly: YoY and growth rate of Cymbalta 2013-2015 ($ millions)
Exhibit 41: Eli Lilly: YoY and growth rate of Zyprexa 2013-2015 ($ millions)
Exhibit 42: Eli Lilly: YoY and growth rate of Strattera 2013-2015 ($ millions)
Exhibit 43: Eli Lilly: YoY and growth rate of Cialis 2013-2015 ($ millions)
Exhibit 44: Pfizer: Key highlights
Exhibit 45: Pfizer: Strength assessment
Exhibit 46: Pfizer: Strategy assessment
Exhibit 47: Pfizer: Opportunity assessment
Exhibit 48: Pfizer: YoY and growth rate of Pristiq 2013-2015 ($ millions)
Exhibit 49: Pfizer: YoY and growth rate of Zoloft 2013-2015 ($ millions)
Exhibit 50: Pfizer: YoY and growth rate of Effexor 2013-2015 ($ millions)
Exhibit 51: Pfizer: YoY and growth rate of Viagra 2013-2015 ($ millions)
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Acerus Pharmaceuticals
  • BMS
  • Euthymics Bioscience
  • Ion Channel Innovations
  • Novan
  • S1 Biopharma
  • MORE
New Report Released: – Global Lifestyle Drugs Market 2017-2021

The author of the report recognizes the following companies as the key players in the global lifestyle drugs market: Allergan, BMS, Eli Lilly, and Pfizer.

Other Prominent Vendors in the market are: Acerus Pharmaceuticals, Alkermes, Amorepacific, AndroScience, Anterios, AstraZeneca, Avanir Pharmaceuticals, Avolynt, Celtaxsys, Cerecor, Corcept Therapeutics, Cosmo Pharmaceuticals, CTC Bio, Dermira, Dong-A ST, Euthymics Bioscience, Foamix, Follicum, Forendo Pharma, Futura Medical Developments, Galderma, Hanmi Pharmaceutical, Incyte, Intrepid Therapeutics, Ion Channel Innovations, iX Biopharma, Johnson & Johnson, Legacy Healthcare, LEO Pharma, H. Lundbeck, Luye America Pharmaceuticals, Merck, Minerva Neurosciences, MSI Methylation Sciences, Neuralstem, Novan, Novartis, Novo-Nordisk, Palatin Technologies, Paratek Pharmaceuticals, Photocure, Revance Therapeutics, Rhythm Pharmaceuticals, S1 Biopharma, Sage Therapeutics, Samumed, Sanofi, Sigma-Tau Pharmaceuticals, Strategic Science & Technologies, Sumitomo Dainippon Pharma, Takeda, TetraLogic Pharmaceuticals, TherapeuticsMD, Valeant Pharmaceuticals, VistaGen Therapeutics, VIVUS, XBiotech, Yuhan, and Zafgen.

Commenting on the report, an analyst from the research team said: “One trend in the market is the increase in M&A. The market has been witnessing an increase in M&A, which will lead to further consolidation. The vendors are pursuing inorganic growth strategies such as acquisitions and/or partnerships to expand their lifestyle drugs portfolio and to improve their presence in the market. For instance, in August 2015, Allergan completed the acquisition of Naurex. The acquisition enhanced Allergan’s portfolio of depression drugs with the addition of rapastinel, a Phase III-ready molecule that demonstrated rapid and sustained efficacy in multiple Phase II clinical studies in depression. With the patent expires in the market place, vendors are also looking to enhance their portfolio through acquisition of generics.

According to the report, one driver in the market is the lifestyle changes. Lifestyle changes such as physical inactivity, stress, consumption of fast foods, and limited intake of water can lead to the development of acne. Research studies report that people who are physically inactive are prone to develop insulin resistance compared with active individuals. Insulin resistance leads to the production of higher levels of sebum in the skin, resulting in acne development. Research studies also put forth that excess insulin can increase the levels of androgens in the body. High levels of androgens also lead to an increased production of sebum in the skin, resulting in acne development.

Further, the report states that one challenge in the market is the patent expiries. The market is currently dominated by key drugs, namely Cymbalta by Eli Lilly, Abilify by Bristol Myers Squibb (BMS), Cialis (tadalafil) by Eli Lilly, Staxyn/Levitra (vardenafil) by Bayer, and Viagra (sildenafil citrate) by Pfizer. The depression drugs such as Cymbalta witnessed a patent expiry in 2013. Due to the patent expiry, Cymbalta reported a YoY decline of 36.36% in 2015. Also, Abilify reported a YoY decline of 63.07% in 2015 due to patent expiration in the US and EU. In addition, the erectile dysfunction drugs Viagra (approved in 1998), Cialis (approved in 2003), Staxyn/Levitra (approved in 2003) drugs were approved long back, and their patents are nearing expiration in the next few years.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Note: Product cover images may vary from those shown
5 of 5
  • Allergan
  • BMS
  • Eli Lilly
  • Pfizer
  • Acerus Pharmaceuticals
  • Alkermes
  • Amorepacific
  • AndroScience
  • Anterios
  • AstraZeneca
  • Avanir Pharmaceuticals
  • Avolynt
  • Celtaxsys
  • Cerecor
  • Corcept Therapeutics
  • Cosmo Pharmaceuticals
  • CTC Bio
  • Dermira
  • Dong-A ST
  • Euthymics Bioscience
  • Foamix
  • Follicum
  • Forendo Pharma
  • Futura Medical Developments
  • Galderma
  • Hanmi Pharmaceutical
  • Incyte
  • Intrepid Therapeutics
  • Ion Channel Innovations
  • iX Biopharma
  • Johnson & Johnson
  • Legacy Healthcare
  • LEO Pharma
  • H Lundbeck
  • Luye America Pharmaceuticals
  • Merck
  • Minerva Neurosciences
  • MSI Methylation Sciences
  • Neuralstem
  • Novan
  • Novartis
  • Novo-Nordisk
  • Palatin Technologies
  • Paratek Pharmaceuticals
  • Photocure
  • Revance Therapeutics
  • Rhythm Pharmaceuticals
  • S1 Biopharma
  • Sage Therapeutics
  • Samumed
  • Sanofi
  • Sigma-Tau Pharmaceuticals
  • Strategic Science & Technologies
  • Sumitomo Dainippon Pharma
  • Takeda
  • TetraLogic Pharmaceuticals
  • TherapeuticsMD
  • Valeant Pharmaceuticals
  • VistaGen Therapeutics
  • VIVUS
  • XBiotech
  • Yuhan
  • Zafgen
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll